AZD1775
Recurrent Medulloblastoma
National Cancer Institute (NCI)Phase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
42 Active assets in the Recurrent Medulloblastoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan Pfizer | Phase 2 | BB |
Olaparib Fundación de investigación HM | Phase 2 | BB |
Nivolumab Bristol-Myers Squibb | Phase 2 | B |
ETOPOSIDE Theodore S. Johnson | Phase 2 | B |
Indoximod Theodore S. Johnson | Phase 2 | B |
View all 50 →
Same molecule, other indications
AZD1775 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →